EP0397671A1 - Ultilisation de milieux contenant des bulles en therapie aux ondes de choc et aux ultra-sons - Google Patents

Ultilisation de milieux contenant des bulles en therapie aux ondes de choc et aux ultra-sons

Info

Publication number
EP0397671A1
EP0397671A1 EP19890900109 EP89900109A EP0397671A1 EP 0397671 A1 EP0397671 A1 EP 0397671A1 EP 19890900109 EP19890900109 EP 19890900109 EP 89900109 A EP89900109 A EP 89900109A EP 0397671 A1 EP0397671 A1 EP 0397671A1
Authority
EP
European Patent Office
Prior art keywords
weight
percent
agent according
mixture
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19890900109
Other languages
German (de)
English (en)
Inventor
Thomas Fritzsch
Joachim Siegert
Volkmar Uhlendorf
Reinhard Schlief
Hans Peter Niendorf
Hans Poland
Eckart Cramer
Doris Ganter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Publication of EP0397671A1 publication Critical patent/EP0397671A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
    • A61B8/48—Diagnostic techniques
    • A61B8/481—Diagnostic techniques involving the use of contrast agent, e.g. microbubbles introduced into the bloodstream
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/223—Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N7/00—Ultrasound therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/22—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for
    • A61B2017/22082—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for after introduction of a substance
    • A61B2017/22088—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for after introduction of a substance ultrasound absorbing, drug activated by ultrasound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/22—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for
    • A61B2017/22082—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for after introduction of a substance
    • A61B2017/22089—Gas-bubbles

Definitions

  • the invention relates to the use of bubble-containing media for shock wave and ultrasound therapy.
  • An effective stone destruction is the electro-hydraulic stone destruction, in which a pressure wave is generated outside the body and is focused on the stone through the body tissue.
  • a pressure wave is generated outside the body and is focused on the stone through the body tissue.
  • waves are generated in liquid by excitation of a spark gap with a damped resonant circuit or with capacitor discharge.
  • the spark gap is surrounded by a focusing reflector.
  • wave generation is e.g. pulsed lasers, piezoelectric or electromagnetic elements.
  • the waves can be focused, in addition to reflection on a semi-ellipsoid, by means of a parabolic arrangement of the energy sources or by bundling with an acoustic lens (F. Eisenberger et al. Urological Stone Therapy, Georg Thieme Verlag Stuttgart 1987 p. 25 ff. And the listed literature) .
  • shock or ultrasonic waves are used as waves for therapy.
  • the invention has for its object to use a means for therapy by means of shock waves and ultrasound with which the total irradiated energy per treatment can be reduced compared to the known methods by increasing the effectiveness at the site of stone destruction to relieve the patient.
  • a suspension with microbubbles consisting of microparticles of a surface-active substance in a liquid carrier or
  • the agent used can advantageously contain microparticles, the surfactant lecithins, polyoxyethylene fatty acid esters, glycerol polyethylene glycol ricinoleate, polyoxyethylene polyoxypropylene polymers, sucrose esters, xyloglycerides, saturated or unsaturated (C44C20) fatty alcohols, saturated or unsaturated (C4-C20) fatty acids Contain salts, mono-, di- and triglycerides, fatty acid esters as microparticles. It is also possible that the agent contains microparticles which contain soybean oil sucrose glyceride or polyethylene glycol sorbitan monostearate as the surfactant.
  • Magnesium stearate, ascorbyl palmitate, sucrose monopalmitate, sucrose monostearate, sucrose distearate or butyl stearate as surface-active substances on average can be used as microparticles with particular advantage be included.
  • the microbubble suspension contains the surfactant in a concentration of 0.001 to 5 percent by weight, preferably 0.04 to 1 percent by weight.
  • the agent can preferably contain cyclodextrins, monosaccharides, disaccharides, trisaccharides, polyols or inorganic or organic salts in a concentration of 2 to 50 percent by weight, preferably 9 to 40 percent by weight.
  • the agent may also contain microparticles which contain dextrose, maltose, galactose, lactose or ⁇ -cyclodextrin in a concentration of 2 to 50 percent by weight, preferably 9 to 40 percent by weight, as a non-surfactant solid.
  • Suitable inorganic or organic salts are sodium chloride, sodium citrate, sodium acetate or sodium tartrate.
  • the smock used as a physiologically acceptable liquid carrier water, physiological electrolyte solution, aqueous solution of mono- or polyhydric alcohols or polyether alcohols or aqueous solution of a mono- or disaccharide or Ringer's solution or Tyrode solution or an aqueous solution of maltose, dextrose , Lactose or galactose.
  • the liquid carrier can particularly advantageously contain glycerol, polyethylene glycol or propylene glycol methyl ether.
  • physiological saline can also be contained in the agent as a physiologically compatible liquid carrier.
  • an agent used according to the invention which contains microparticles of maltose, dextrose, lactose or galactose in a liquid carrier of water, a physiological electrolyte solution such as 0.9% aqueous sodium chloride solution, Ringer's solution or Tyrode solution or an aqueous one Solution of maltose, dextrose, lactose or galactose can contain, without the addition of viscosity-increasing substances such as propylene glycol, a good effect enhancement in shock wave and ultrasound therapy.
  • the agent used according to the invention can contain microparticles of lactose in up to 25% (weight percent) aqueous lactose solution.
  • the agents used according to the invention can also contain microparticles of galactose in up to 20% aqueous galactose solution or microparticles of galactose in water.
  • the agent contains microparticles of a mixture of butyl stearate and galactose in water or a mixture of soybean oil sucrose. contains glyceride and galactose in water or polyethylene glycol sorbitan monostearate and galactose in physiological saline or oleic acid and galactose in physiological saline.
  • an agent used according to the invention is a liquid solution with microbubbles, consisting of the mixture of 0.01 to 10 percent by weight of a surfactant or surfactant mixture with an aqueous or water-miscible carrier liquid and the mixture of 0.5 up to 50 percent by weight of a viscosity-increasing substance or a mixture of substances in an aqueous or water-miscible carrier liquid, the two mixtures being present separately or combined.
  • a means for shock wave and ultrasound therapy can be used with particular advantage, consisting of a mixture of 0.01 to 10 percent by weight of a surfactant or surfactant mixture in an aqueous or water-miscible carrier liquid, the 0.05 to 5 percent by weight of a physiologically compatible carboxylic acid Salt contains and the mixture of 0.5 to 50 percent by weight of a viscosity-increasing substance or a substance mixture with an aqueous or water-miscible carrier liquid which contains an amount equivalent to the carboxylic acid salt physiologically compatible acid.
  • Sodium hydrogen carbonate and potassium hydrogen are particularly found as physiologically compatible carboxylic acid salts carbonate application. Lactic acid, citric acid and pyruvic acid are particularly mentioned as physiologically compatible acids.
  • nonionic surfactants lecithins, lecithin fractions and their modification products, polyoxyethylene fatty acid esters such as polyoxyethylene fatty alcohol ethers, polyoxyethylated sorbitan fatty acid esters, glycerol polyethylene glycol oxystearate, glycerol polyethylene glycol rhizinoleate, ethoxylated soy ethylene oxide polymers, ethoxylated ethoxylated ethoxylated ethoxylated ethoxylated ethoxylated ethylene oxide polymers, with molecular weights 6800-8975, 13300 and 16250 are preferred.
  • Possible ionic surfactants are: quaternary ammonium base, sodium lauryl sulfate, sodium dioctyl sulfosuccinate.
  • Possible viscosity-increasing substances are mono- or polysaccharides such as glucose, levulose, galactose, lactose, sorbitol, mannitol, xylitol, sucrose or dextrans, cyclodextrins, hydroxyethyl starch and polyols. Glycerol, polyglycols, inulin and 1,2-propanediol are used as polyols.
  • protein-like substances amino acids or blood substitutes such as, for example, plasma proteins, gelatin, oxypolygelatin and gelatin derivatives or mixtures thereof are also used.
  • the concentration of these substances mentioned in the solution can be 0.5 to 50 percent by weight, the maximum concentration also depending on the solute.
  • glucose or lactose at a concentration of 0.5 to 50 percent by weight can be used, whereas gelatin has a preferred concentration of 0.5 to 2 percent by weight.
  • the oxypolygelatin is preferably used in a concentration of 0.5 to 10 percent by weight.
  • surfactants which at the same time increase the viscosity, such as, for example, polyoxyethylene-polyoxypropylene polymers with the molecular weight from 4750 to 16250.
  • the concentration of the surfactants with a viscosity-increasing effect is 1 to 20 percent by weight, preferably 3 to 10 percent by weight.
  • the surfactant or surfactant mixture is preferably dissolved in a carrier liquid in the presence of the viscosity-increasing substance or substance mixtures.
  • Water can be used as the carrier liquid or aqueous solutions which are physiologically compatible, such as, for example, physiological electrolyte solutions such as physiological saline, can be mixed with water or polyhydric alcohols, Ringer's solution, Tyrode's solution or the aqueous solutions of sodium chloride, calcium chloride, sodium hydrogen carbonate, sodium citrate, sodium acetate or sodium tartrate or salt solutions, as are usually used as infusion solutions, or mixtures thereof.
  • physiological electrolyte solutions such as physiological saline
  • the abovementioned means are used for any form of extracorporeal shock wave lithotripsy (ESWL). They are excellent for reinforcing the crushing of kidneys and gallstones.
  • the agents are transported to the target organs by retrograde or antegrade application.
  • the agent is introduced retrograde into the kidney, the urine must first be withdrawn via a catheter that is introduced into the kidney via the ureter. After the urine has been removed, the agent (2 - 50 ml depending on the volume of the kidney) is introduced into the kidney in order to be removed from the kidney after a short residence time of approx. 0.5 to 2 minutes. The kidney is then filled with a physiologically compatible solution. Irradiation using elastomechanical vibrations (shock waves, ultrasonic waves) for the purpose of stone destruction can now join.
  • the means is brought into the immediate vicinity of the stone in the case of retrograde working.
  • the stone surface is specifically provided with the middle solution (volume: 0.1 - 5 ml).
  • the stone is deliberately coated with the middle solution (volume of the applied solution: 1 - 5 ml). Irradiation by elastomechanical vibrations can now follow.
  • the agent is introduced into the kidney using a puncture needle and removed after a short residence time (0.5-2 minutes) and then exposed to the vibrations.
  • the cavities of the target organs for example kidney, bile
  • the desired success of lithotripsy is not achieved.
  • the numerous microbubbles absorb and scatter the radiated elastomechanical vibration on the stones. The incident waves do not reach the destination, the stone, with sufficient energy.
  • the properties of the agents cause the microbubbles of the agent, for example by adhesive forces on the upper, in a procedure as described under a) stick to the surface of the stones.
  • the subsequent displacement by means of a physiologically compatible solution displaces only the agent from the organ space; the microbubbles adhering to the stones remain in sufficient quantity.
  • stones that are covered with a microbubble layer and that are (stone + bubbles) in the physiologically compatible solution are then stones that are covered with a microbubble layer and that are (stone + bubbles) in the physiologically compatible solution. If the elastomechanical vibrations are now radiated in, the energy of these vibrations is absorbed by the bubbles adhering to the stone and used to break up the stone.
  • Treatment of gallstones is possible in an analogous manner, for example, using antegrade or retrograde puncture using known methods.
  • a human gallstone is introduced into the second focus of the elipsoid in a sample vessel.
  • the sample vessel is then filled with the agent (20 ml of a 25% galactose suspension in water).
  • the galactose suspension is then removed from the sample vessel by means of a plunger and the sample vessel is filled with 20 ml of physiological saline.
  • the concrement in the sample vessel is now exposed to the shock waves. After only nine impacts, this stone fell into many small fragments.
  • the experimental set-up is the same as in Example 1. However, the gallstone (same size as in Example 1) was not treated with the galactose agent, but was immediately introduced into the physiological saline solution. After 100 impacts of the same energy applied to the stone, no stone fragmentation was achieved.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Acoustics & Sound (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Utilisation de suspensions ou de solutions contenant des micro-bulles en thérapie aux ondes de choc et aux ultra-sons. Lorsque l'on utilise ces agents, la lithotripsie par rayonnement d'ondes de choc et d'ultra-sons effectuée pour soulager le patient se fait avec moins d'énergie que lorsque l'on ne les utilise pas.
EP19890900109 1987-12-02 1988-12-02 Ultilisation de milieux contenant des bulles en therapie aux ondes de choc et aux ultra-sons Withdrawn EP0397671A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19873741199 DE3741199A1 (de) 1987-12-02 1987-12-02 Verwendung von ultraschallkontrastmitteln fuer die ultraschall-lithotripsie
DE3741199 1987-12-02

Publications (1)

Publication Number Publication Date
EP0397671A1 true EP0397671A1 (fr) 1990-11-22

Family

ID=6341916

Family Applications (2)

Application Number Title Priority Date Filing Date
EP88730269A Pending EP0322350A1 (fr) 1987-12-02 1988-12-02 Utilisation de milieux contenant des bulles dans la thérapie utilisant des ondes de choc et des ultrasons
EP19890900109 Withdrawn EP0397671A1 (fr) 1987-12-02 1988-12-02 Ultilisation de milieux contenant des bulles en therapie aux ondes de choc et aux ultra-sons

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP88730269A Pending EP0322350A1 (fr) 1987-12-02 1988-12-02 Utilisation de milieux contenant des bulles dans la thérapie utilisant des ondes de choc et des ultrasons

Country Status (4)

Country Link
EP (2) EP0322350A1 (fr)
JP (1) JPH03505723A (fr)
DE (1) DE3741199A1 (fr)
WO (1) WO1989005160A1 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149319A (en) * 1990-09-11 1992-09-22 Unger Evan C Methods for providing localized therapeutic heat to biological tissues and fluids
US7083778B2 (en) 1991-05-03 2006-08-01 Bracco International B.V. Ultrasound contrast agents and methods of making and using them
US6989141B2 (en) 1990-05-18 2006-01-24 Bracco International B.V. Ultrasound contrast agents and methods of making and using them
USRE39146E1 (en) 1990-04-02 2006-06-27 Bracco International B.V. Long-lasting aqueous dispersions or suspensions of pressure-resistant gas-filled microvesicles and methods for the preparation thereof
US6613306B1 (en) 1990-04-02 2003-09-02 Bracco International B.V. Ultrasound contrast agents and methods of making and using them
US5215680A (en) * 1990-07-10 1993-06-01 Cavitation-Control Technology, Inc. Method for the production of medical-grade lipid-coated microbubbles, paramagnetic labeling of such microbubbles and therapeutic uses of microbubbles
EP0504881B2 (fr) * 1991-03-22 2000-11-08 Katsuro Tachibana Amplificateur pour la thérapie des maladies à ultrason et composition pharmaceutique liquide le contenant
US5798091A (en) 1993-07-30 1998-08-25 Alliance Pharmaceutical Corp. Stabilized gas emulsion containing phospholipid for ultrasound contrast enhancement
ES2231775T5 (es) 1993-07-30 2011-02-02 Imcor Pharmaceutical Co. Composición de microburbujas estabilizadas para ecografía.
DE4406474A1 (de) * 1994-02-23 1995-08-24 Schering Ag Gas enthaltende Mikropartikel, diese enthaltende Mittel, deren Verwendung in der Ultraschalldiagnostik, sowie Verfahren zur Herstellung der Partikel und Mittel
US5540909A (en) * 1994-09-28 1996-07-30 Alliance Pharmaceutical Corp. Harmonic ultrasound imaging with microbubbles
US5804162A (en) * 1995-06-07 1998-09-08 Alliance Pharmaceutical Corp. Gas emulsions stabilized with fluorinated ethers having low Ostwald coefficients
US6582392B1 (en) 1998-05-01 2003-06-24 Ekos Corporation Ultrasound assembly for use with a catheter
GB9800813D0 (en) 1998-01-16 1998-03-11 Andaris Ltd Improved ultrasound contrast imaging method and apparatus
ATE520362T1 (de) 2001-12-03 2011-09-15 Ekos Corp Katheter mit mehreren ultraschall-abstrahlenden teilen
US8226629B1 (en) 2002-04-01 2012-07-24 Ekos Corporation Ultrasonic catheter power control
US7341569B2 (en) 2004-01-30 2008-03-11 Ekos Corporation Treatment of vascular occlusions using ultrasonic energy and microbubbles
US8012457B2 (en) 2004-06-04 2011-09-06 Acusphere, Inc. Ultrasound contrast agent dosage formulation
US10548659B2 (en) 2006-01-17 2020-02-04 Ulthera, Inc. High pressure pre-burst for improved fluid delivery
US9358033B2 (en) 2005-09-07 2016-06-07 Ulthera, Inc. Fluid-jet dissection system and method for reducing the appearance of cellulite
US9011473B2 (en) 2005-09-07 2015-04-21 Ulthera, Inc. Dissection handpiece and method for reducing the appearance of cellulite
US9486274B2 (en) 2005-09-07 2016-11-08 Ulthera, Inc. Dissection handpiece and method for reducing the appearance of cellulite
US8518069B2 (en) 2005-09-07 2013-08-27 Cabochon Aesthetics, Inc. Dissection handpiece and method for reducing the appearance of cellulite
US7967763B2 (en) 2005-09-07 2011-06-28 Cabochon Aesthetics, Inc. Method for treating subcutaneous tissues
US7885793B2 (en) 2007-05-22 2011-02-08 International Business Machines Corporation Method and system for developing a conceptual model to facilitate generating a business-aligned information technology solution
US9248317B2 (en) 2005-12-02 2016-02-02 Ulthera, Inc. Devices and methods for selectively lysing cells
US20070265560A1 (en) 2006-04-24 2007-11-15 Ekos Corporation Ultrasound Therapy System
US10182833B2 (en) 2007-01-08 2019-01-22 Ekos Corporation Power parameters for ultrasonic catheter
ES2471118T3 (es) 2007-06-22 2014-06-25 Ekos Corporation Método y aparato para el tratamiento de hemorragias intracraneales
US8439940B2 (en) 2010-12-22 2013-05-14 Cabochon Aesthetics, Inc. Dissection handpiece with aspiration means for reducing the appearance of cellulite
US11096708B2 (en) 2009-08-07 2021-08-24 Ulthera, Inc. Devices and methods for performing subcutaneous surgery
US9358064B2 (en) 2009-08-07 2016-06-07 Ulthera, Inc. Handpiece and methods for performing subcutaneous surgery
US10656025B2 (en) 2015-06-10 2020-05-19 Ekos Corporation Ultrasound catheter

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3173476D1 (en) * 1980-11-17 1986-02-20 Schering Ag Composition generating microbubbles
DE3141641A1 (de) * 1981-10-16 1983-04-28 Schering Ag, 1000 Berlin Und 4619 Bergkamen Ultraschall-kontrastmittel und dessen herstellung
DE3313946A1 (de) * 1983-04-15 1984-10-18 Schering AG, 1000 Berlin und 4709 Bergkamen Mikropartikel und gasblaeschen enthaltende ultraschall-kontrastmittel
DE3313947A1 (de) * 1983-04-15 1984-10-18 Schering AG, 1000 Berlin und 4709 Bergkamen Mikropartikel und gasblaeschen enthaltende ultraschall-kontrastmittel
DE3324754A1 (de) * 1983-07-06 1985-01-17 Schering AG, 1000 Berlin und 4709 Bergkamen Ultraschallkontrastmittel sowie dessen herstellung
US4989588A (en) * 1986-03-10 1991-02-05 Olympus Optical Co., Ltd. Medical treatment device utilizing ultrasonic wave
DE3637926C1 (de) * 1986-11-05 1987-11-26 Schering Ag Ultraschall-Manometrieverfahren in einer Fluessigkeit mittels Mikroblaeschen

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO8905160A1 *

Also Published As

Publication number Publication date
EP0322350A1 (fr) 1989-06-28
JPH03505723A (ja) 1991-12-12
WO1989005160A1 (fr) 1989-06-15
DE3741199C2 (fr) 1989-11-23
DE3741199A1 (de) 1989-08-17

Similar Documents

Publication Publication Date Title
EP0397671A1 (fr) Ultilisation de milieux contenant des bulles en therapie aux ondes de choc et aux ultra-sons
EP0389543B1 (fr) Procede et agent d'operation par ondes ultrasoniques ou par ondes de choc
EP0296189B1 (fr) Procede manometrique par ultrasons dans un liquide au moyen de microbulles
US6113570A (en) Method of removing thrombosis in fistulae
US5695460A (en) Enhancement of ultrasound thrombolysis
EP0077752B1 (fr) Mélange liquide pour l'absorption et la stabilisation de vésicules de gaz utilisée comme agent de contraste pour le diagnostic par ultrasons et son procédé de préparation
JPH02252449A (ja) 気泡の内部破壊により生体内部の柔組織および骨を含む細胞の選択的破懐装置
DE3300121A1 (de) Verfahren und geraet zum abbilden und thermischen behandeln von gewebe mittels ultraschall
EP0226740A1 (fr) Dispositif pour thromboser au moyen d'ondes de choc
DE3709404C2 (fr)
Koga et al. Cumulative Renal Damage in Oogs by Repeated Treatment with Extracorporeal Shock Waves
Debus et al. Treatment of the Dunning prostate rat tumor R3327-AT1 with pulsed high energy ultrasound shock waves (PHEUS): Growth delay and histomorphologic changes
DE3814743C2 (de) Einrichtung zur Auflösung von Konkrementen in einer Körperhöhle
DE3921808C2 (fr)
DE19625164A1 (de) Vorrichtung zum Auflösen von Thromben
EP0282727A2 (fr) Chimiolyse de concrétions
DE3812837A1 (de) Bauelement fuer extracorporales einbringen von stosswellen
US4931038A (en) Complex of products for the rapid and not-invasive treatment of biliary calculosis
Nicolaides et al. Shock Waves in Vascular Diseases An in-Vitro Study
IL127967A (en) Flushing solution for surgery using ultrasound energy
DE60009356T2 (de) Biokompatible injektierbare wässerige Lösung zur Verwendung bei ultraschallenergieunterstützter Chirurgie
Prystowsky et al. Extracorporeal shock wave lithotripsy for biliary stones
Li et al. Experiments with extracorporeal shock wave nephrolithotripsy
DE29623722U1 (de) Vorrichtung zum Auflösen von Thromben

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19890621

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

RBV Designated contracting states (corrected)

Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE

XX Miscellaneous (additional remarks)

Free format text: VERBUNDEN MIT 88730269.3/0322350 (EUROPAEISCHE ANMELDENUMMER/VEROEFFENTLICHUNGSNUMMER) DURCH ENTSCHEIDUNG VOM 14.01.91.

17Q First examination report despatched

Effective date: 19911010

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19920908